January 29, 2013 at 16:55 PM EST
Verisante Technology, Inc. Retains Crescendo Communications for Investor Relations

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 29, 2013) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, today announced that it has retained Crescendo Communications, LLC ("Crescendo") to help increase investor awareness throughout North America.

"We are pleased and excited to start working with Verisante, whose breakthrough skin cancer detection device has the potential to save millions of lives through early detection. Not only has the Aura(TM) been recently approved for sale in Canada, Europe and Australia, but U.S. approval is now underway. Moreover, the technology is applicable to lung, gastro-intestinal, colorectal, cervical and other cancers, which represent sizable yet untapped markets. For this reason, we believe it is a great time to begin increasing awareness of Verisante in advance of a number of important financial and other milestones we expect this year. We believe the significant potential of their proprietary technology, coupled with a well-crafted commercialization strategy, will resonate well within the investment community," commented David Waldman, President & CEO of Crescendo.

"The team at Crescendo has extensive experience within the healthcare market and a successful track record working with small-cap public companies throughout North America," said Thomas Braun, President & CEO of Verisante. "We are confident that Crescendo will help us proactively communicate our business model and upcoming milestones as we move into the next stage of our development."

The agreement with Crescendo is for a period of 12 months. Under the terms of the agreement, the Company will pay a consulting fee to Crescendo of $6,000 per month plus approved expenses incurred on behalf of the Company.

About Crescendo Communications, LLC

Crescendo Communications, LLC, headquartered in New York City with offices in Beijing, Shanghai and Moscow, is an emerging leader within the investor relations industry. The firm was founded on a strategic and professional approach to investor relations that builds awareness of public companies through tailored outreach programs that target institutional investors, analysts, and the financial media. The firm's approach is centered around properly educating investors and cultivating trust in order to uphold and protect their clients' long-term credibility and reputation on Wall Street and within the global capital markets.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura(TM) for skin cancer detection and the Verisante Core(TM) series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura(TM) has been approved for sale in Canada, Europe and Australia. The Core(TM) has not yet been approved for sale.

Verisante Aura(TM) was awarded Popular Science Magazine's "Best of What's New Award" for 2011, and Verisante Core(TM) was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.

Forward-Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact:

Verisante Technology, Inc.

Thomas Braun

President & CEO

(604) 605-0507

info@verisante.com

www.verisante.com

YouTube: www.youtube.com/verisante

Twitter: www.twitter.com/verisante

Facebook: www.facebook.com/verisante

Crescendo Communications, LLC

David Waldman/Natalya Rudman

Investor Relations

(212) 671-1020 x304

VRS@crescendo-ir.com

www.crescendo-ir.com

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here